XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research

Zacks Research upgraded shares of XOMA Royalty (NASDAQ:XOMA) from a strong sell rating to a hold rating in a research report released on Wednesday,Zacks.com reports.

A number of other research firms have also issued reports on XOMA. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $97.00 target price on shares of XOMA Royalty in a report on Friday, March 20th. TD Cowen raised XOMA Royalty to a “hold” rating in a report on Friday, February 13th. Finally, Stifel Nicolaus set a $50.00 target price on XOMA Royalty in a report on Friday, December 12th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $61.60.

XOMA Royalty Stock Performance

XOMA opened at $36.74 on Wednesday. The firm has a market capitalization of $437.94 million, a P/E ratio of 25.16 and a beta of 0.68. The stock’s 50 day moving average price is $27.86 and its two-hundred day moving average price is $30.04. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 1.15. XOMA Royalty has a 12-month low of $19.38 and a 12-month high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last released its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.16. The firm had revenue of $13.76 million for the quarter, compared to analyst estimates of $11.13 million. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%. On average, equities analysts forecast that XOMA Royalty will post -1.41 earnings per share for the current year.

Hedge Funds Weigh In On XOMA Royalty

A number of hedge funds have recently made changes to their positions in XOMA. Barclays PLC lifted its holdings in shares of XOMA Royalty by 12.1% during the 4th quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 1,598 shares during the period. Rhumbline Advisers lifted its holdings in shares of XOMA Royalty by 18.0% during the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 2,019 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of XOMA Royalty by 66.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,755 shares of the biotechnology company’s stock worth $286,000 after acquiring an additional 4,278 shares during the period. Man Group plc bought a new position in shares of XOMA Royalty during the 3rd quarter worth about $247,000. Finally, Squarepoint Ops LLC bought a new position in shares of XOMA Royalty during the 4th quarter worth about $237,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.